Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Amarpreet Sawhney
AddedMar 31, 2024
UpdatedJun 28, 2026
Amarpreet Sawhney

Amarpreet Sawhney

Co-Founder, Ocular Therapeutix

Crunchbase

Amarpreet Sawhney's Career

Ocular Therapeutix
Ocular Therapeutix

Bedford, MA, US

Co-Founder
Rejoni
Rejoni

Bedford, MA, US

Founder & CEO· C-Suite · Management
Instylla
Instylla

Bedford, MA, US

Founder

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Amarpreet Sawhney's Career

Ocular Therapeutix
Ocular Therapeutix
Public$386.5M2742006Bedford, MA, US
Co-Founder

Leadership at Ocular Therapeutix

Antony MattessichAntony MattessichBoard Member
Merilee RainesMerilee RainesBoard Member
Fred KhosraviFred KhosraviCo-Founder
Leslie J WilliamsLeslie J WilliamsBoard Member
Charles WardenCharles WardenBoard Member
Richard L LindstromRichard L LindstromBoard Member

Similar to Ocular Therapeutix

Ocular ScienceOcular ScienceManhattan Beach, CA, USEye Care Productsest. 2015Ocular ScienceManhattan Beach, CA, US · est. 2015

Ocular Science®: A leading biotech firm innovating affordable eye care solutions.

Seed · $175.1k46
Hyperion DeFiHyperion DeFiNew York City, NY, USTherapeuticsest. 2014Hyperion DeFiNew York City, NY, US · est. 2014

Eyenovia, Inc.: A NASDAQ-listed biopharmaceutical firm innovating advanced ophthalmic therapeutics.

Public · $75.1M41
OcuCure TherapeuticsOcuCure TherapeuticsRoanoke, VA, USEye Drops, Pharmaceuticalsest. 2005OcuCure TherapeuticsRoanoke, VA, US · est. 2005

OcuCure Therapeutics: Developing innovative eye drops for age-related and diabetic eye diseases since 2005.

Public · $3.3M8
EyeCyteEyeCyteLos Angeles, CA, USTherapeuticsest. 2005EyeCyteLos Angeles, CA, US · est. 2005

EyeCyte: Developing novel therapeutics for neovascular and degenerative retinal diseases.

Series A · $3M5
Rejoni
Rejoni
Series B$41.3M152020Bedford, MA, US
Founder & CEO· C-Suite · Management

Similar to Rejoni

RijuvenRijuvenWexford, PA, USMedical Devicesest. 2012RijuvenWexford, PA, US · est. 2012

Rijuven: Innovating portable diagnostic devices to revolutionize care delivery and reduce costs.

Angel · $3.8M30
Juvent - Regenerative TechnologiesJuvent - Regenerative TechnologiesOoltewah, TN, USMedical Devicesest. 2011Juvent - Regenerative TechnologiesOoltewah, TN, US · est. 2011

Regenerative Technologies Corp. offers non-invasive Juvent devices for improved musculoskeletal health.

Pre-Seed · $2.7M30
Minerva SurgicalMinerva SurgicalSanta Clara, CA, USMedical Devicesest. 2008Minerva SurgicalSanta Clara, CA, US · est. 2008

US-based Minerva offers a comprehensive suite of devices for minimally invasive treatment of Abnormal Uterine Bleeding.

Public · $173.9M189
Rinovum Women's HealthRinovum Women's HealthMonroeville, PA, USMedical Devicesest. 2014Rinovum Women's HealthMonroeville, PA, US · est. 2014

Rinovum Womens Health LLC develops and manufactures at-home natural conception aids.

Series C · $29.7M30
Instylla
Instylla
Series C$63.5M422017Bedford, MA, US
Founder

Leadership at Instylla

Darshana ZaveriDarshana ZaveriBoard Member
Tasneem DohadwalaTasneem DohadwalaBoard Member
Dr. Amarpreet S. Sawhney - Year 2009Dr. Amarpreet S. Sawhney - Year 2009CEO

Similar to Instylla

Instent ConnectionInstent ConnectionSeattle, WA, USMedical DevicesInstent ConnectionSeattle, WA, US

Creating absorbent stents for GI procedures to improve patient outcomes.

Angel · $7.5k50
EmbolxEmbolxSunnyvale, CA, USMedical Devicesest. 2013EmbolxSunnyvale, CA, US · est. 2013

Embolx: A medical device startup innovating in cancer treatment with novel embolization microcatheters.

Seed · $2.5M12
EmboMedicsEmboMedicsMaple Grove, MN, USMedical Devicesest. 2012EmboMedicsMaple Grove, MN, US · est. 2012

EmboMedics: Developing and commercializing resorbable, drug-loaded embolization devices since 2012.

Pre-Seed · $7.6M5
EmStopEmStopBrainerd, MN, USMedical Devicesest. 2021EmStopBrainerd, MN, US · est. 2021

Brainerd-based manufacturer specializing in medical devices.

Seed · $3.5M5

Amarpreet Sawhney's Co-Investors

Richard BraddockRichard BraddockCo-invested · Axtria Series C

Amarpreet Sawhney's Similar Executives & Operators

Achmad ZakyAchmad ZakyCo-Founder · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakWillix HalimWillix HalimCEO · BukalapakWILL WEI CHENGWILL WEI CHENGCo-Founder · DiDiBo ZhangBo ZhangCo-Founder · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniFounder · Reliance RetailKim Beom-sooKim Beom-sooCo-Founder · KakaoBrian KimBrian KimCo-Founder · Kakao

People Similar to Amarpreet Sawhney

Justin ShakaJustin ShakaCo-Founder · RebionGary ONeilGary ONeilCo-Founder · RejjeeJames WangJames WangFounder & CEO · ReaiK. Paul SinghK. Paul SinghCo-Founder · INNOVATESourav GoswamiSourav GoswamiCo-Founder & CEO · ReAlphaPeter A. StrittmatterPeter A. StrittmatterCo-Founder · REhnu